

Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	318345	BLACKMORES PROBIOTICS+ IMMUNE DEFENCE
ARTG entry for	Medicine Listed	
Sponsor	Blackmores Ltd	
Postal Address	PO Box 1725, V Australia	VARRIEWOOD, NSW, 2102
ARTG Start Date	4/06/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicine	S

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . BLACKMORES PROBIOTICS+ IMMUNE DEFENCE

Product Type	Single Medicine Product	Effective Date	8/09/2022
Permitted Indications	•		
Maintain/support gener	ral health and wellbeing		
Maintain/support intest	inal health		
Maintain/support health	ny mucous linings of the digestive system		
Maintain/support intest	inal good/beneficial/friendly flora		
Helps maintain/support	t good/beneficial/friendly gut flora during antibiotic use		
Help restore good/bene	eficial/friendly gut flora after antibiotic use		
Helps restore good/ber	neficial/friendly intestinal/gut/bowel flora		
Nourish good/beneficia	l/friendly intestinal flora		
Maintain/support gastro	pintestinal system health		
Maintain/support immu	ne system health		
Maintain/support health	ny immune system function		
Maintain/support health	ny gastrointestinal immune function		
Decrease/reduce/reliev	ve common cold duration		
Decrease/reduce/reliev	ve symptoms of common cold		
Indication Requireme	nts		

Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza. Product presentation must not imply or refer to serious immunological diseases.

Label statement: If symptoms persist, talk to your health professional.

Label statement: Adults only, OR Not to be used in children under 2 years of age without medical advice (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Page 1 of 2

This is not an ARTG Certificate document.

Produced at 04.01.2023 at 04:10:04 AEDT

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Adults only. OR Not to be used in children under two years of age without medical advice (or words to that effect).

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information

Pack Size		Poison Schedule	
Components			
1. Formulation 1			
Dosage Form	Capsule, hard		
Route of Administration	Oral		
Visual Identification	Olai		
Active Ingredients			
ascorbic acid		200 mg	
Bifidobacterium animalis s	sp lactis	4.275 billion CFU	
Bifidobacterium bifidum		225 million CFU	
Bifidobacterium lactis		2 billion CFU	
inulin		100 mg	
Lactobacillus acidophilus		6.75 billion CFU	
Lactobacillus acidophilus		6.75 billion CFU	
zinc citrate dihydrate		16.2 mg	
Equivalent: zinc		5 mg	
Other Ingredients (Excipie	nts)		
colloidal anhydrous silica			
dibasic potassium phosph	ate		
disodium edetate			
gellan gum			
hypromellose			
magnesium stearate			
microcrystalline cellulose			
monobasic potassium pho	sphate		
potable water			
potassium acetate			
sucrose			
trehalose dihydrate			

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information